Egalet Receives U.S. Patent

Pharmaceutical company Egalet has received a U.S. patent for its proprietary Guardian Technology tablet architecture used to create delivery of combination products with immediate-, delayed- and/or extended-release properties.

Shares of Egalet were up nearly 10% in pre-market trading, though had eased to being up just 2% shortly after the open of trading Monday. “The newly issued patent adds to the flexibility for what we can do with future products and partnerships using our Guardian Technology,” said Bob Radie, CEO of Egalet. “This technology puts us at an advantage to create more sophisticated delivery systems for many different kinds of pharmaceutical products.”